Skip to main content
Uncategorized

Ysios leads €29.2 Million Series D Financing of AM-Pharma

By 13 de September de 2011November 18th, 2020No Comments
< Back to news
 13.09.2011

Ysios leads €29.2 Million Series D Financing of AM-Pharma

Ysios Capital Partners, the Spanish life sciences venture capital firm –located at the Barcelona Scientific Park– announces that is has led the €29.2 million Series D financing of AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) as a treatment of severe inflammatory diseases.


Ysios Capital Partners, the Spanish life sciences venture capital firm, today announces that is has led the €29.2 million Series D financing of AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) as a treatment of severe inflammatory diseases. The oversubscribed series D round was led by Ysios Capital Partners, co-led by Kurma Life Science Partners and supported by a consortium including the venture arms of two global Healthcare companies, Abbott and Shire, the European venture funds, BB Biotech Ventures and Idinvest Partners as well as existing investors, Forbion Capital Partners and Inventages Venture Capital.

The current fundraising will enable AM-Pharma to advance its human recombinant form of human AP from preclinical stages through to the end of phase II as a treatment for Acute Kidney Injury (AKI). AKI is a serious condition in which the kidney function is damaged by severe inflammation (sepsis), surgery or contrast fluids. This kidney damage may then lead to patients undergoing dialysis treatment for the rest of their lives. Currently there is no effective treatment for AKI and over 700.000 AKI patients die each year. The AKI market represents a USD 2 billion opportunity. AP, an enzyme playing a protective role in anti-inflammatory conditions, has shown great potency in two AKI clinical phase II studies as well as in one Ulcerative Colitis study with bovine-derived AP. The new human recombinant AP that AM-Pharma developed will be assessed for its safety and efficacy during clinical development.

Joël Jean-Mairet of Ysios, Rémi Droller of Kurma Life Sciences Partners and Klaus Breiner of BB Biotech Ventures will join and further strengthen the existing Supervisory Board comprising of Ashok Dhanrajgir, Bart Bergstein, David Brister and Eric Claassen.

“We were delighted to have the opportunity to participate in this financing. AM-Pharma is exploring an indication of high unmet need with a truly innovative product that has shown to be effective and safe in the clinical POC trials. This is a pivotal moment to be investing in a company focused on a condition with such an attractive market opportunity”, Joël Jean-Mairet said, cofounding Partner of Ysios Capital Partners.

Erik van der Berg, CEO of AM-Pharma, commented: “This financing round builds on recent good phase II data with bovine Alkaline Phosphatase for the treatment of acute kidney injury. We are particularly pleased to have our approach validated through the additional support of large pharma.”